A new laser treatment for hard-to-treat glaucoma can lower eye pressure just as well as the older method, but with far less pain and swelling. That’s the key finding from a new head-to-head comparison in people who had run out of other options.
Glaucoma is a leading cause of irreversible blindness worldwide. It damages the optic nerve, often because pressure inside the eye rises too high. Many people manage it with eye drops, laser procedures, or surgery. But for some, standard treatments stop working. This is called refractory glaucoma, and it can be stressful for patients and their doctors.
The older laser approach, called continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), has been used for decades to lower eye pressure by reducing fluid production inside the eye. It works, but it can be painful and cause prolonged inflammation. That’s where the newer micropulse version (MP-TSCPC) comes in.
Here’s the twist: the micropulse laser delivers energy in short bursts rather than a constant beam. Think of it like a light switch turned on and off rapidly instead of left on all the time. This pattern gives the eye tissue time to cool between pulses, which may protect the surface and reduce side effects. The goal is the same—lower eye pressure—but the path is gentler.
In this study, researchers enrolled 52 patients with refractory glaucoma and randomly assigned them to receive either the micropulse laser or the continuous-wave laser. Each group had 26 patients at the start. Patients were followed for 18 months, and the study was single-blind, meaning patients didn’t know which laser they received. The main measures were eye pressure, the number of glaucoma medications needed, vision stability, quality of life, and side effects.
By the end of the study, 47 patients completed follow-up: 24 in the micropulse group and 23 in the continuous-wave group. Eye pressure dropped by about 34% in the micropulse group and about 43% in the continuous-wave group. The difference was small and just missed statistical significance, which suggests both lasers can lower pressure effectively.
Success rates were similar between the two groups. Complete success—meaning eye pressure stayed in the target range without any medications—was 25% for micropulse and 22% for continuous-wave. Qualified success—pressure controlled with the help of eye drops—was 29% for micropulse and 39% for continuous-wave. Combined, about 54% of micropulse patients and 61% of continuous-wave patients achieved success with or without medications. None of these differences were statistically significant.
But the safety profile told a different story. Nearly 57% of continuous-wave patients reported postoperative pain, compared with just 21% in the micropulse group. Prolonged inflammation was also more common with the continuous-wave laser (35% vs. 8%). Visual function stayed stable in both groups, and quality of life improved more in the micropulse group, though the between-group difference was not statistically significant.
This doesn’t mean this treatment is available yet.
An important caveat is that this was a small, single-center study with an 18-month follow-up. Larger, longer trials are needed to confirm these findings and to see how the lasers perform in a wider range of patients. The study also used a single-blind design, which helps reduce bias but doesn’t eliminate it.
Still, the results fit with a growing trend toward gentler glaucoma procedures. Micropulse laser technology has been explored for several eye conditions, and this study adds evidence that it can match the pressure-lowering effect of the older method while improving comfort. For patients who need additional treatment beyond drops or surgery, that could mean a more tolerable option.
What this means for you: If you have refractory glaucoma and are considering laser treatment, ask your eye doctor whether micropulse cyclophotocoagulation is available and whether you might be a candidate. It’s not a cure, and it won’t replace drops or surgery for everyone, but it could help lower pressure with fewer side effects. As always, discuss the risks and benefits with your care team.
What happens next: Researchers will need larger, multi-center trials to confirm these results and to refine treatment protocols. Insurance coverage and regulatory approval will also depend on more data. For now, the micropulse approach looks promising as a balanced option that offers similar pressure control with a better safety profile.
